Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GT Biopharma, Inc. (GTBP)
USD0.35
-0.02 (-5.04%)
US NASDAQ Healthcare Biotechnology
Address
8000 Marina Boulevard 94005
San Francisco, CA, US
San Francisco, CA, US
CEO
Michael Martin Breen
Website
gtbiopharma.com
IPO
2018-03-27
CIK 109657 ISIN US36254L3087
Also trades on
Euronext Paris · GTBP.PA (EUR)
NASDAQ Capital Market · GTBP (USD)
Description
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, they maintain a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies utilizing their TriKE technology. Founded in 1965, the company previously operated as OXIS International, Inc. before rebranding to GT Biopharma, Inc. in July 2017. Its corporate operations are based in Brisbane, California.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.35
-0.02 (-5.04%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
0.86
Float Shares
10.30M
Free Float %
97.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -10.25% | +3.66% | +3.93% | -13.81% | -42.69% | -49.83% | -82.42% | -95.35% | -99.90% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (5 ratings, all time)
Buy
Price Targets & DCF
Current price
0.35
DCF (Unlevered)
1.11
+216.5%
DCF (Levered)
1.24
+252.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-111.99
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+9.9% Q1'26: +66.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +848.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+190.6% Q1'26: +1,191.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 13.00M (-100.0%)
|
—
est: 13.50M (-100.0%)
|
9.70M
9.70M – 9.70M
-28.1% YoY
|
67.70M
67.70M – 67.70M
+597.9% YoY
|
—
— – —
-100.0% YoY
|
20.07M
20.07M – 20.07M
|
59.88M
59.88M – 59.88M
+198.3% YoY
|
| EBITDA |
-13.16M
|
-34.32M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-13.16M
|
-34.32M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.16M
est: -37.44M (+64.8%)
|
-28.35M
est: -9.15M (-209.8%)
|
-1.87M
-1.87M – -1.87M
+79.5% YoY
|
-1.49M
-1.49M – -1.49M
+20.6% YoY
|
-1.27M
-1.27M – -1.27M
+14.8% YoY
|
275.7K
275.7K – 275.7K
+121.7% YoY
|
1.98M
1.98M – 1.98M
+620.0% YoY
|
| SGA |
8.57M
|
8.95M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-6.94
est: -6.79 (-2.2%)
|
-6.25
est: -1.66 (-276.5%)
|
-0.34
-0.34 – -0.34
+79.5% YoY
|
-0.27
-0.27 – -0.27
+20.6% YoY
|
-0.23
-0.23 – -0.23
+14.8% YoY
|
0.05
0.05 – 0.05
+121.7% YoY
|
0.36
0.36 – 0.36
+620.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.61M
OE per share TTM
-14.84
Owner's Yield
-138.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
593.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
20
Total invested
382.8K
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Anshuman Dube | 251.10M | 62.70% | — | 251.10M | — | 10.00 | IN | United States of America | 2011-03-29 | ↗ |
| 2 | Theorem Group, LLC | 251.10M | 62.70% | — | 251.10M | — | 10.00 | PN | California | 2011-03-29 | ↗ |
| 3 | Bristol Investment Fund, Ltd. | 54.39M | 9.19% | 54.39M | — | 54.39M | 11.00 | CO | Cayman Islands | 2015-02-11 | ↗ |
| 4 | Heavener, James W | 4.67M | 8.70% | 4.67M | — | 4.67M | — | OO | United States | 2019-02-05 | ↗ |
| 5 | Paul Kessler | 4.00M | 0.68% | 4.00M | — | 4.00M | 11.00 | IN | United States | 2015-02-11 | ↗ |
| 6 | Investment Fund, Ltd. 98-0335509 | 3.85M | 11.00% | 3.85M | — | 3.85M | — | CO | Cayman Islands | 2010-02-16 | ↗ |
| 7 | Armistice Capital, LLC | 3.68M | 9.99% | — | 3.68M | — | — | IA, OO | Delaware | 2023-02-14 | ↗ |
| 8 | Steven Boyd | 3.68M | 9.99% | — | 3.68M | — | — | HC, IN | United States of America | 2023-02-14 | ↗ |
| 9 | Theorem Group, LLC 20-3192094 | 3.54M | 7.10% | 3.54M | — | 3.54M | — | OO | United States | 2017-11-14 | ↗ |
| 10 | Bristol Investment Fund, Ltd. 98-0335509 | 2.08M | 9.84% | — | — | — | — | CO | Cayman Islands | 2016-01-25 | ↗ |
| 11 | Elliot Bossen | 1.77M | 4.00% | 1.77M | — | 1.77M | — | IN | United States of America | 2007-02-14 | ↗ |
| 12 | Alpha Capital Anstalt | 265.2K | 0.87% | 265.2K | — | 265.2K | — | CO | Liechtenstein | 2022-01-18 | ↗ |
| 13 | GAMCO Asset Management Inc. | 171.6K | 0.47% | 8.17M | — | 8.17M | — | IA, CO | United States | 2017-12-04 | ↗ |
| 14 | Paul L. Kessler | 1.00 | 1.06% | — | — | — | — | IN | Cayman Islands | 2022-03-03 | ↗ |
| 15 | Diana Derycz-Kessler | — | 0.90% | — | — | — | — | IN | Cayman Islands | 2022-03-03 | ↗ |
| 16 | Bigger Capital Fund GP, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2022-01-28 | ↗ |
| 17 | Bigger Capital Fund, LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-01-28 | ↗ |
| 18 | Bristol Capital, LLC 95-4717240 | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2022-03-03 | ↗ |
| 19 | District 2 Capital Fund LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-01-28 | ↗ |
| 20 | District 2 Capital LP | — | 0.00% | — | — | — | — | PN | Delaware | 2022-01-28 | ↗ |
| 21 | District 2 GP LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2022-01-28 | ↗ |
| 22 | District 2 Holdings LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2022-01-28 | ↗ |
| 23 | Michael Bigger | — | 0.00% | — | — | — | — | IN | Delaware | 2022-01-28 | ↗ |
| 24 | Silverback Asset Management, LLC | — | 0.00% | — | — | — | — | OO | Delaware | 2007-02-14 | ↗ |
| 25 | Silverback Master, Ltd. | — | 0.00% | — | — | — | — | CO | Cayman Islands | 2007-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
20
-18 vs prev Q
New positions
8
Closed positions
26
Increased
10
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC | 80.8K +41.1K (+103.8%) | 63.4K +39.9K (+169.1%) | 2.05% +0.620 pp | 0.00% +0.000 pp | USD0.69 +14.5% | 4 qtrs — |
| 2 | SCIENTECH RESEARCH LLC | 54.7K +54.7K (+100.0%) | 43.0K +43.0K (+100.0%) | 1.39% +1.389 pp | 0.03% +0.027 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 3 | SEACREST WEALTH MANAGEMENT, LLC | 50.0K +50.0K (+100.0%) | 36.6K +36.6K (+100.0%) | 1.27% +1.269 pp | 0.00% +0.004 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 4 | JANE STREET GROUP, LLC | 26.0K +26.0K (+100.0%) | 20.4K +20.4K (+100.0%) | 0.66% +0.660 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 5 | INTEGRATED WEALTH CONCEPTS LLC | 20.0K +20.0K (+100.0%) | 15.7K +15.7K (+100.0%) | 0.51% +0.508 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 19.3K -4.7K (-19.6%) | 15.1K +873.0 (+6.1%) | 0.49% -0.376 pp | 0.00% +0.000 pp | USD3.21 -75.4% | 8 qtrs — |
| 7 | MORGAN STANLEY | 18.6K +4.6K (+32.7%) | 14.6K +6.4K (+77.7%) | 0.47% -0.034 pp | 0.00% +0.000 pp | USD1.20 -34.2% | 8 qtrs — |
| 8 | COSTON, MCISAAC & PARTNERS | 17.1K +17.1K (+100.0%) | 13.0K +13.0K (+100.0%) | 0.43% +0.434 pp | 0.00% +0.003 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 9 | CAITLIN JOHN, LLC | 16.5K +16.5K (+100.0%) | 13.0K +13.0K (+100.0%) | 0.42% +0.419 pp | 0.01% +0.009 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 10 | WELLS FARGO & COMPANY/MN | 16.0K +6.0K (+60.2%) | 12.6K +6.7K (+114.4%) | 0.41% +0.046 pp | 0.00% +0.000 pp | USD2.99 -73.6% | 8 qtrs — |
| 11 | AM INVESTMENT STRATEGIES LLC | 15.0K +15.0K (+100.0%) | 12.0K +12.0K (+100.0%) | 0.38% +0.381 pp | 0.00% +0.003 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 12 | CERITY PARTNERS LLC | 15.0K +15.0K (+100.0%) | 11.8K +11.8K (+100.0%) | 0.38% +0.381 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 13 | VERDENCE CAPITAL ADVISORS LLC | 13.0K +13.0K (+100.0%) | 10.2K +10.2K (+100.0%) | 0.33% +0.330 pp | 0.00% +0.001 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 14 | TWO SIGMA SECURITIES, LLC | 12.5K -4.5K (-26.6%) | 9.8K -167.0 (-1.7%) | 0.32% -0.298 pp | 0.00% 0.000 pp | USD0.59 +33.9% | 2 qtrs — |
| 15 | PROSPERA FINANCIAL SERVICES INC | 12.0K +12.0K (+100.0%) | 9.4K +9.4K (+100.0%) | 0.30% +0.304 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 16 | HRT FINANCIAL LP | 11.8K +11.8K (+100.0%) | 9.0K +9.0K (+100.0%) | 0.30% +0.299 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 17 | PARSONS CAPITAL MANAGEMENT INC/RI | 10.9K +10.9K (+100.0%) | 8.6K +8.6K (+100.0%) | 0.28% +0.277 pp | 0.00% +0.001 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 18 | BANK OF MONTREAL /CAN/ | 10.8K -81.7K (-88.3%) | 8.5K -46.1K (-84.4%) | 0.27% -3.063 pp | 0.00% +0.000 pp | USD3.61 -78.1% | 8 qtrs — |
| 19 | LPL FINANCIAL LLC | 10.6K +10.6K (+100.0%) | 8.3K +8.3K (+100.0%) | 0.27% +0.270 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 20 | ADVISORY SERVICES NETWORK, LLC | 10.0K +10.0K (+100.0%) | 7.9K +7.9K (+100.0%) | 0.25% +0.254 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 21 | BLACKROCK, INC. | 8.4K -1.3K (-13.6%) | 6.6K +892.0 (+15.6%) | 0.21% -0.138 pp | 0.00% +0.000 pp | USD2.31 -65.8% | 6 qtrs — |
| 22 | HBK SORCE ADVISORY LLC | 10.0K +10.0K (+100.0%) | 5.4K +5.4K (+100.0%) | 0.25% +0.254 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 23 | WOLFF WIESE MAGANA LLC | 5.0K +5.0K (+100.0%) | 3.9K +3.9K (+100.0%) | 0.13% +0.127 pp | 0.00% +0.002 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 24 | NEWBRIDGE FINANCIAL SERVICES GROUP, INC. | 3.8K +— (+0.0%) | 2.9K +746.0 (+33.9%) | 0.10% -0.040 pp | 0.00% +0.000 pp | USD2.53 -68.8% | 5 qtrs — |
| 25 | FARTHER FINANCE ADVISORS, LLC | 3.0K +3.0K (+100.0%) | 2.4K +2.4K (+100.0%) | 0.08% +0.076 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 26 | CITIGROUP INC | 2.8K +2.8K (+100.0%) | 2.2K +2.2K (+100.0%) | 0.07% +0.071 pp | 0.00% +0.000 pp | USD0.78 +1.3% | 1 qtrs NEW |
| 27 | ADVISOR GROUP HOLDINGS, INC. | 2.0K -3.1K (-60.6%) | 1.6K -3.1K (-66.3%) | 0.05% -0.132 pp | 0.00% +0.000 pp | USD3.45 -77.1% | 8 qtrs — |
| 28 | CIBC PRIVATE WEALTH GROUP, LLC | 2.0K +2.0K (+100.0%) | 1.6K +1.6K (+100.0%) | 0.05% +0.051 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 29 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.7K -3.0 (-0.2%) | 1.3K +337.0 (+33.7%) | 0.04% -0.018 pp | 0.00% +0.000 pp | USD1.42 -44.4% | 8 qtrs — |
| 30 | TRIUMPH CAPITAL MANAGEMENT | 1.7K +1.7K (+100.0%) | 1.3K +1.3K (+100.0%) | 0.04% +0.042 pp | 0.00% +0.000 pp | USD0.78 +1.3% | 1 qtrs NEW |
| 31 | SPIRE WEALTH MANAGEMENT | 994.00 +994.0 (+100.0%) | 785.00 +785.0 (+100.0%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD0.78 +1.3% | 1 qtrs NEW |
| 32 | SWAN CAPITAL LLC | 1.0K +1.0K (+100.0%) | 785.00 +785.0 (+100.0%) | 0.03% +0.025 pp | 0.00% +0.000 pp | USD0.79 +0.0% | 1 qtrs NEW |
| 33 | BANK OF AMERICA CORP /DE/ | 24.00 +— (+0.0%) | 19.00 +5.0 (+35.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.63 -78.2% | 8 qtrs — |
| 34 | BNP PARIBAS ARBITRAGE, SNC | 16.00 +— (+0.0%) | 13.00 +4.0 (+44.4%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD3.75 -78.9% | 8 qtrs — |
| 35 | SBI SECURITIES CO., LTD. | 1.00 -4.0 (-80.0%) | 1.00 -2.0 (-66.7%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD2.00 -60.5% | 5 qtrs — |
| 36 | ALLWORTH FINANCIAL LP | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD3.00 -73.7% | 5 qtrs — |
| 37 | UBS GROUP AG | 1.00 -2.6K (-100.0%) | 1.00 -1.5K (-99.9%) | 0.00% -0.095 pp | 0.00% +0.000 pp | USD3.00 -73.7% | 8 qtrs — |
| 38 | JPMORGAN CHASE & CO | 1.00 +— (+0.0%) | 1.00 +— (+0.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD4.00 -80.3% | 8 qtrs — |
| 39 | CLEARSTEAD ADVISORS, LLC | — -865.0 (-100.0%) | — -508.0 (-100.0%) | 0.00% -0.031 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
| 40 | BLUE BELL PRIVATE WEALTH MANAGEMENT, LLC | — -10.0 (-100.0%) | — -6.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 41 | DRW SECURITIES, LLC | — -142.4K (-100.0%) | — -83.5K (-100.0%) | 0.00% -5.137 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
| 42 | VANGUARD GROUP INC | — -10.5K (-100.0%) | — -6.3K (-100.0%) | 0.00% -0.379 pp | 0.00% +0.000 pp | USD— | 8 qtrs SOLD |
| 43 | JONES FINANCIAL COMPANIES LLLP | — -300.0 (-100.0%) | — -230.0 (-100.0%) | 0.00% -0.011 pp | 0.00% +0.000 pp | USD— | 3 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 1 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 175.9K | 0.05% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
100.0K
Shares disposed
—
Cash buys
2.00
Cash sales
—
Net activity
+100,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-09-04 | URBAN ALAN LOUIS | Officer | A-Award | A | Option to purchase Common Stock | 50,000 | 1.33 | 66.5K | 50,000 | D | ↗ |
| 2025-09-04 | Mun-Gavin David C. | Director | A-Award | A | Option to purchase Common Stock | 31,250 | 1.33 | 41.6K | 31,250 | D | ↗ |
| 2025-09-04 | Kramer Hilary | Director | A-Award | A | Option to purchase Common Stock | 31,250 | 1.33 | 41.6K | 31,250 | D | ↗ |
| 2025-09-04 | CASAMENTO CHARLES J | Director | A-Award | A | Option to purchase Common Stock | 62,500 | 1.33 | 83.1K | 62,500 | D | ↗ |
| 2025-09-04 | Breen Michael Martin | Director / Officer | A-Award | A | Option to purchase Common Stock | 100,000 | 1.33 | 133.0K | 100,000 | D | ↗ |
| 2025-06-10 | Mun-Gavin David C. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-08 | Ritter Andrew J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-07 | Kramer Hilary | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-17 | URBAN ALAN LOUIS | Officer | A-Award | A | Option to purchase Common Stock | 23,335 | 2.11 | 49.2K | 23,335 | D | ↗ |
| 2024-06-03 | URBAN ALAN LOUIS | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-08-11 | Ohri Manu | Officer | J-Other | A | Common Stock | 200,000 | 0.29 | 57.4K | 300,000 | — | ↗ |
| 2023-08-11 | Breen Michael Martin | Director / Officer | A-Award | A | Common Stock | 200,000 | 0.29 | 57.4K | 856,218 | — | ↗ |
| 2023-06-16 | CASAMENTO CHARLES J | Director | A-Award | A | Option to purchase Common Stock | 500,000 | 0.35 | 175.0K | 500,000 | — | ↗ |
| 2023-05-01 | CASAMENTO CHARLES J | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-04-11 | Breen Michael Martin | Director / Officer | P-Purchase | A | Common Stock | 50,000 | 0.50 | 25.0K | 656,218 | — | ↗ |
| 2023-04-06 | Ohri Manu | Officer | P-Purchase | A | Common Stock | 50,000 | 0.50 | 25.0K | 50,000 | — | ↗ |
| 2023-01-27 | Wendel Bruce | Director | A-Award | A | Option to purchase Common Stock | 500,000 | 0.84 | 418.5K | 500,000 | — | ↗ |
| 2023-01-27 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Option to purchase Common Stock | 500,000 | 0.84 | 418.5K | 500,000 | — | ↗ |
| 2023-01-27 | Ohri Manu | Officer | A-Award | A | Option to purchase Common Stock | 500,000 | 0.84 | 418.5K | 500,000 | — | ↗ |
| 2023-01-27 | Breen Michael Martin | Director / Officer | A-Award | A | Option to purchase Common Stock | 500,000 | 0.84 | 418.5K | 500,000 | — | ↗ |
| 2022-07-15 | Wendel Bruce | Director | A-Award | A | Option to purchase Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-07-15 | URBAN ALAN LOUIS | Director | A-Award | A | Option to purchase Common Stock | 50,000 | 2.48 | 124.0K | 50,000 | — | ↗ |
| 2022-07-15 | SHROTRIYA RAJESH C MD | Director | A-Award | A | Option to purchase Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-07-15 | Ohri Manu | Officer | J-Other | D | Common Stock | 100,000 | 0.00 | — | 0 | — | ↗ |
| 2022-07-15 | Breen Michael Martin | Officer | A-Award | A | Option to purchase Common Stock | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-07-15 | Berk Gregory | Officer | A-Award | A | Option to purchase Common Stock | 50,000 | 2.48 | 124.0K | 50,000 | — | ↗ |
| 2022-06-09 | URBAN ALAN LOUIS | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-02-14 | Ohri Manu | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-12-31 | Choy Gavin | — | A-Award | A | Option to purchase Common Stock | 227,500 | 3.05 | 693.9K | 227,500 | — | ↗ |
| 2021-11-28 | Choy Gavin | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-02-25 | Breen Michael Martin | — | C-Conversion | A | Common Stock | 9,859 | 3.40 | 33.5K | 328,160 | — | ↗ |
| 2021-02-16 | Wendel Bruce | — | A-Award | A | Common Stock | 347,572 | 0.00 | — | 352,655 | — | ↗ |
| 2021-02-16 | SHROTRIYA RAJESH C MD | — | A-Award | A | Option to purchase Common Stock | 50,000 | 6.33 | 316.5K | 50,000 | — | ↗ |
| 2021-02-16 | Breen Michael Martin | — | A-Award | A | Common Stock | 278,058 | 0.00 | — | 278,058 | — | ↗ |
| 2021-02-16 | Berk Gregory | — | A-Award | A | Option to purchase Common Stock | 50,000 | 6.33 | 316.5K | 50,000 | — | ↗ |
| 2021-01-13 | SHROTRIYA RAJESH C MD | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-12-22 | Wendel Bruce | — | P-Purchase | A | Common Stock | 441 | 8.73 | 3.8K | 5,083 | — | ↗ |
| 2020-12-22 | Weldon Steven W | — | S-Sale | D | Common Stock | 47,978 | 0.40 | 19.2K | 3,720,000 | — | ↗ |
| 2020-12-21 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.0K | 3,853,700 | — | ↗ |
| 2020-12-18 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.0K | 3,903,700 | — | ↗ |
| 2020-12-17 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.0K | 4,003,700 | — | ↗ |
| 2020-12-16 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.0K | 4,053,700 | — | ↗ |
| 2020-12-15 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.30 | 15.0K | 4,203,700 | — | ↗ |
| 2020-12-14 | Weldon Steven W | — | S-Sale | D | Common Stock | 46,300 | 0.29 | 13.4K | 4,253,700 | — | ↗ |
| 2020-12-11 | Weldon Steven W | — | S-Sale | D | Common Stock | 50,000 | 0.25 | 12.5K | 4,450,000 | — | ↗ |
| 2020-11-16 | Wendel Bruce | — | P-Purchase | A | Common Stock | 3,268 | 3.14 | 10.3K | 3,268 | — | ↗ |
| 2020-11-11 | Wendel Bruce | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-11-11 | Berk Gregory | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-23 | Breen Michael Martin | — | — | D | 10% Senior Convertible Debenture | 0 | 3.40 | — | 0 | — | ↗ |
| 2020-06-02 | Cataldo Tony | Director / Officer / 10% Owner | S-Sale | D | common stock | 4,234,320 | 0.00 | 4.2K | 6,500,000 | — | ↗ |
| 2020-05-13 | Weldon Steven W | Director / Officer | S-Sale | D | common stock | 2,269,708 | 0.00 | 2.3K | 4,500,000 | — | ↗ |
| 2019-08-14 | Weldon Steven W | Director / Officer / 10% Owner | A-Award | A | common stock | 4,500,000 | 0.00 | — | 6,769,707 | — | ↗ |
| 2019-08-14 | Cataldo Tony | Director / Officer / 10% Owner | A-Award | A | common stock | 7,000,000 | 0.00 | — | 10,734,320 | — | ↗ |
| 2019-02-06 | Cataldo Tony | Director | S-Sale | D | common stock | 800,000 | 0.00 | 800.00 | 4,029,600 | — | ↗ |
| 2019-02-01 | Urbanski Raymond W. | Director / Officer | S-Sale | D | common stock | 176,980 | 0.00 | 176.98 | 1,351,918 | — | ↗ |
| 2017-11-16 | Cross Shawn | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-11-02 | Cataldo Tony | Director / Officer / 10% Owner | G-Gift | D | common stock | 200,000 | 0.00 | — | 4,943,029 | — | ↗ |
| 2017-09-01 | Weldon Steven W | Director / Officer | A-Award | A | common stock | 2,566,835 | 0.00 | — | 2,568,840 | — | ↗ |
| 2017-09-01 | Urbanski Raymond W. | Officer | — | D | common stock | 0 | 0.00 | — | 1,528,989 | — | ↗ |
| 2017-09-01 | Silverman Mark J | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 8,172,079 | — | ↗ |
| 2017-09-01 | Clarence-Smith Kathleen | Director / Officer / 10% Owner | — | D | common stock | 0 | 0.00 | — | 8,505,633 | — | ↗ |
| 2017-09-01 | Cataldo Tony | Director / Officer / 10% Owner | A-Award | A | common stock | 5,129,660 | 0.00 | — | 5,143,029 | — | ↗ |
| 2016-04-05 | BRISTOL INVESTMENT FUND LTD | 10% Owner | J-Other | A | Common Stock | 250,000 | 0.00 | — | 463,806 | — | ↗ |
| 2016-04-04 | BRISTOL INVESTMENT FUND LTD | 10% Owner | S-Sale | D | Common Stock | 675,000 | 303,750.00 | 205.03B | 1,525,472 | — | ↗ |
| 2016-02-09 | BRISTOL INVESTMENT FUND LTD | 10% Owner | — | D | Common stock | 0 | 0.00 | — | 2,563,689 | — | ↗ |
| 2016-01-25 | Weldon Steven W | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 601,610 | — | ↗ |
| 2016-01-25 | Cataldo Tony | Director / Officer / 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 4,033,531 | — | ↗ |
| 2016-01-13 | BRISTOL INVESTMENT FUND LTD | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 2,441,148 | — | ↗ |
| 2012-03-01 | Saloff David | Director / Officer | A-Award | A | Common Stock Option | 26,334,193 | 0.04 | 1.05M | 27,650,684 | — | ↗ |
| 2011-08-31 | Saloff David | Director / Officer | A-Award | A | Common Stock Option | 538,713 | 0.05 | 28.8K | 1,316,491 | — | ↗ |
| 2011-06-30 | Saloff David | Director | — | D | Common Stock Option | 777,778 | 0.09 | 70.0K | 0 | — | ↗ |
| 2011-06-27 | Eaton Kenneth Haynes | Director | — | D | Common Stock Option | 250,000 | 0.09 | 22.5K | 0 | — | ↗ |
| 2011-05-20 | DUBE ANSHUMAN | Director | P-Purchase | A | 12% Convertible Debenture due 2012 | 0 | 0.10 | — | 250,000 | — | ↗ |
| 2010-12-27 | Theorem Group, LLC | 10% Owner | S-Sale | D | Common Stock | 360,100 | 0.13 | 47.2K | 0 | — | ↗ |
| 2010-12-27 | DUBE ANSHUMAN | Director / 10% Owner | S-Sale | D | Common Stock | 360,100 | 0.13 | 47.2K | 0 | — | ↗ |
| 2010-12-23 | Theorem Group, LLC | 10% Owner | S-Sale | D | Common Stock | 339,900 | 0.13 | 44.2K | 360,100 | — | ↗ |
| 2010-12-23 | DUBE ANSHUMAN | Director / 10% Owner | C-Conversion | D | 0% Convertible Debenture | 700,000 | 0.05 | 35.0K | 1,100,000 | — | ↗ |
| 2010-10-01 | HOOG THOMAS W | Director | — | D | Non-qualified Stock Option (right to buy) | 250,000 | 0.11 | 27.5K | 0 | — | ↗ |
| 2010-08-31 | Post Gary M | — | S-Sale | D | Common Stock | 69,600 | 0.11 | 7.7K | 900,000 | — | ↗ |
| 2010-08-30 | Post Gary M | — | S-Sale | D | Common Stock | 30,940 | 0.11 | 3.4K | 969,600 | — | ↗ |
| 2010-08-26 | Post Gary M | — | S-Sale | D | Common Stock | 76,060 | 0.12 | 9.0K | 1,000,540 | — | ↗ |
| 2010-07-08 | Post Gary M | Director / Officer | S-Sale | D | Common Stock | 50,000 | 0.11 | 5.4K | 1,076,600 | — | ↗ |
| 2010-07-07 | Post Gary M | Director / Officer | S-Sale | D | Common Stock | 55,000 | 0.11 | 5.8K | 1,286,600 | — | ↗ |
| 2010-05-30 | Landes Bernard | Officer | — | D | Non-qualified Stock Option (right to buy) | 2,220,453 | 0.17 | 377.5K | 0 | — | ↗ |
| 2010-05-30 | Handelman Michael D | Officer | — | D | Non-qualified Stock Option (right to buy) | 250,000 | 0.17 | 42.5K | 0 | — | ↗ |
| 2010-03-29 | Post Gary M | Director | A-Award | A | Non-qualified Stock Option (right to buy) | 1,110,227 | 0.17 | 188.7K | 1,539,810 | — | ↗ |
| 2010-03-29 | Cataldo Tony | Director / Officer | — | D | Non-qualified Stock Option (right to buy) | 6,704,081 | 0.17 | 1.14M | 0 | — | ↗ |
| 2010-01-26 | Post Gary M | Director | X-InTheMoney | D | Non-qualified Stock Option (right to buy) | 100,000 | 0.23 | 23.0K | 429,583 | — | ↗ |
| 2010-01-19 | Post Gary M | Director | A-Award | A | Common Stock | 1,500,000 | 0.23 | 345.0K | 1,500,000 | — | ↗ |
| 2009-10-23 | DUBE ANSHUMAN | Director / 10% Owner | — | I | Series H Convertible Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-10-13 | Theorem Group, LLC | 10% Owner | — | D | Series H Convertible Preferred Stock | 0 | 0.00 | — | 0 | — | ↗ |
| 2009-10-01 | Theorem Group, LLC | 10% Owner | — | D | Series A Warrant | 1,800,000 | 0.06 | 112.5K | 0 | — | ↗ |
| 2009-10-01 | DUBE ANSHUMAN | Director / 10% Owner | — | I | 0% Convertible Debenture | 1,800,000 | 0.05 | 90.0K | 0 | — | ↗ |
| 2007-12-31 | HAUSMAN MARVIN S MD | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2007-11-09 | SPOLAR MATTHEW R | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.10 | 500.00 | 35,000 | — | ↗ |
| 2007-11-09 | REPINE JOHN E | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.10 | 500.00 | 482,187 | — | ↗ |
| 2007-11-09 | Post Gary M | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.10 | 500.00 | 529,583 | — | ↗ |
| 2007-11-09 | NEILL SYDNEY COLIN | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.10 | 500.00 | 432,500 | — | ↗ |
| 2007-01-11 | SPOLAR MATTHEW R | Director | A-Award | A | Stock Option | 30,000 | 0.22 | 6.6K | 30,000 | — | ↗ |
| 2006-11-06 | REPINE JOHN E | Director | A-Award | A | Common Stock | 50,000 | 0.18 | 9.0K | 50,000 | — | ↗ |
| 2006-11-06 | Post Gary M | Director | A-Award | A | Common Stock Warrant (right to buy) | 173,608 | 0.20 | 34.7K | 281,608 | — | ↗ |
| 2006-11-06 | NEILL SYDNEY COLIN | Director / Officer | A-Award | A | Common Stock Warrant (right to buy) | 187,500 | 0.20 | 37.5K | 427,500 | — | ↗ |
| 2006-11-06 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 495,000 | 0.20 | 99.0K | 1,209,695 | — | ↗ |
| 2006-10-12 | REPINE JOHN E | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 9,787 | 0.24 | 2.3K | 77,187 | — | ↗ |
| 2006-10-12 | Post Gary M | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 156,250 | 0.24 | 37.5K | 191,250 | — | ↗ |
| 2006-10-12 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Common Stock | 330,769 | 0.20 | 67.5K | 330,769 | — | ↗ |
| 2006-08-01 | REPINE JOHN E | Director | A-Award | A | Non-Qualified Stock Option | 5,000 | 0.27 | 1.4K | 67,400 | — | ↗ |
| 2006-08-01 | Post Gary M | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.27 | 1.4K | 35,000 | — | ↗ |
| 2006-08-01 | NEILL SYDNEY COLIN | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 5,000 | 0.27 | 1.4K | 240,000 | — | ↗ |
| 2006-08-01 | HAUSMAN MARVIN S MD | Director | A-Award | A | Non-Qualified Stock Option | 5,000 | 0.27 | 1.4K | 714,695 | — | ↗ |
| 2006-08-01 | CENTRON MICHAEL D | Officer | A-Award | A | Incentive Stock Option (right to buy) | 100,000 | 0.27 | 27.0K | 250,000 | — | ↗ |
| 2006-05-12 | Post Gary M | Director | P-Purchase | A | Common Stock Warrant (right to buy) | 108,000 | 0.39 | 42.1K | 108,000 | — | ↗ |
| 2006-03-15 | Post Gary M | Director | — | D | Non-Statutory Stock Option (Right to Purchase) | 30,000 | 0.31 | 9.3K | 0 | — | ↗ |
| 2006-01-06 | CENTRON MICHAEL D | Officer | — | D | Non-Statutory Stock Option (right to purchase) | 150,000 | 0.30 | 45.0K | 0 | — | ↗ |
| 2005-12-28 | RODELL TIMOTHY C JR | Director | A-Award | A | Non-Statutory Stock Option (right to purchase) | 100,000 | 0.29 | 29.0K | 455,237 | — | ↗ |
| 2005-12-28 | REPINE JOHN E | Director | A-Award | A | Non-Statutory Stock Option (right to purchase) | 30,000 | 0.29 | 8.7K | 62,400 | — | ↗ |
| 2005-12-28 | NEILL SYDNEY COLIN | Director | A-Award | A | Non-Statutory Stock Option (right to buy) | 100,000 | 0.29 | 29.0K | 235,000 | — | ↗ |
| 2005-12-28 | HAUSMAN MARVIN S MD | Director | A-Award | A | Non-Statutory Stock Option (right to purchase) | 500,000 | 0.29 | 145.0K | 709,695 | — | ↗ |
| 2005-12-28 | Guillen Steven T | Director / Officer | A-Award | A | Non-Statutory Stock Option (right to buy) | 500,000 | 0.29 | 145.0K | 1,100,000 | — | ↗ |
| 2005-10-05 | REPINE JOHN E | Director | — | D | Non-Statutory Stock Option (Right to Purchase) | 30,000 | 0.37 | 11.1K | 0 | — | ↗ |
| 2005-10-05 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Non-Statutory Stock Option (Right to Buy) | 108,000 | 0.37 | 40.0K | 0 | — | ↗ |
| 2005-06-22 | RODELL TIMOTHY C JR | Director | A-Award | A | stock option (right to buy) | 5,000 | 0.34 | 1.7K | 355,237 | — | ↗ |
| 2005-06-22 | NEILL SYDNEY COLIN | Director | A-Award | A | stock option (right to buy) | 5,000 | 0.34 | 1.7K | 135,000 | — | ↗ |
| 2005-06-22 | HAUSMAN MARVIN S MD | Director / Officer | A-Award | A | Stock Option Grant (right to buy) | 5,000 | 0.34 | 1.7K | 101,695 | — | ↗ |
| 2005-02-28 | Guillen Steven T | Director / Officer | A-Award | A | Stock Option-Right to buy (NQSO) | 100,000 | 0.40 | 40.0K | 1,200,000 | — | ↗ |
| 2004-12-24 | ODonnell Manus H | Officer | A-Award | A | Stock Option-Right to Buy | 100,000 | 0.59 | 59.0K | 100,000 | — | ↗ |
| 2004-10-12 | VLAK GERARD J M | Director | A-Award | A | stock option (right to buy) | 50,000 | 0.59 | 29.5K | 85,000 | — | ↗ |
| 2004-10-12 | RODELL TIMOTHY C JR | Director | A-Award | D | stock option (right to buy) | 50,000 | 0.59 | 29.5K | 350,237 | — | ↗ |
| 2004-10-12 | NEILL SYDNEY COLIN | Director | A-Award | A | stock option (right to buy) | 100,000 | 0.59 | 59.0K | 135,000 | — | ↗ |
| 2004-10-12 | HAUSMAN MARVIN S MD | Director | A-Award | A | stock option (right to buy) | 50,000 | 0.59 | 29.5K | 85,000 | — | ↗ |
| 2004-10-12 | FERRIS STEVEN H | Director | A-Award | A | stock option (right to buy) | 50,000 | 0.59 | 29.5K | 85,000 | — | ↗ |
| 2004-10-12 | BRUINSMA GOSSE B | Director / Officer | A-Award | A | stock option (right to buy) | 100,000 | 0.59 | 59.0K | 135,000 | — | ↗ |
| 2004-08-20 | HAUSMAN MARVIN S MD | Director | — | I | Common Stock | 0 | 0.00 | — | 13,982,567 | — | ↗ |
| 2004-06-22 | RODELL TIMOTHY C JR | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.57 | 8.6K | 311,237 | — | ↗ |
| 2004-06-22 | ODonnell Manus H | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2004-06-22 | DAVIS RICHARD A | Director | A-Award | A | Stock Option (right to buy) | 15,000 | 0.57 | 8.6K | 117,147 | — | ↗ |
| 2004-04-26 | VLAK GERARD J M | Director | A-Award | A | Common Stock | 30,000 | 0.69 | 20.7K | 30,000 | — | ↗ |
| 2004-04-26 | NEILL SYDNEY COLIN | Director | A-Award | A | Common Stock | 30,000 | 0.69 | 20.7K | 30,000 | — | ↗ |
| 2004-04-26 | FERRIS STEVEN H | Director | A-Award | A | Common Stock | 30,000 | 0.69 | 20.7K | 30,000 | — | ↗ |
| 2004-04-26 | BRUINSMA GOSSE B | Director | A-Award | D | Common Stock | 30,000 | 0.69 | 20.7K | 30,000 | — | ↗ |
| 2004-04-25 | VLAK GERARD J M | Director | — | I | Common Stock | 0 | 0.00 | — | 13,982,567 | — | ↗ |
| 2004-04-25 | NEILL SYDNEY COLIN | Director | — | I | Common Stock | 0 | 0.00 | — | 13,982,567 | — | ↗ |
| 2004-04-25 | FERRIS STEVEN H | Director | — | I | Common Stock | 0 | 0.00 | — | 13,982,567 | — | ↗ |
| 2004-04-25 | BRUINSMA GOSSE B | Director | — | I | Common Stock | 0 | 0.00 | — | 13,982,567 | — | ↗ |
| 2004-01-15 | AXONYX INC | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 13,912,571 | — | ↗ |
| 2003-12-04 | WOLF THOMAS M | Director | A-Award | D | Stock Option (right to buy) | 12,280 | 0.57 | 7.0K | 90,780 | — | ↗ |
| 2003-12-04 | WEBB TED FORD | Director | A-Award | D | Stock Option (right to buy) | 0 | 0.57 | — | 30,000 | — | ↗ |
| 2003-12-04 | ROGERS RAY R | Officer | G-Gift | D | Common Stock | 10,000 | 0.48 | 4.8K | 1,677,988 | — | ↗ |
| 2003-12-04 | RODELL TIMOTHY C JR | Director | A-Award | D | Stock Option (right to buy) | 24,035 | 0.57 | 13.7K | 295,237 | — | ↗ |
| 2003-12-04 | PRYOR WILLIAM G | Director | A-Award | D | Stock Option (right to buy) | 17,602 | 0.57 | 10.0K | 87,602 | — | ↗ |
| 2003-12-04 | ELLIS SHARON | Officer | A-Award | A | Stock Option (right to buy) | 150,000 | 0.56 | 84.0K | 885,000 | — | ↗ |
| 2003-12-04 | DAVIS RICHARD A | Director | A-Award | D | stock option (right to buy) | 59,368 | 0.57 | 33.8K | 84,368 | — | ↗ |
| 2003-11-26 | ROGERS RAY R | Officer | G-Gift | D | Common Stock | 10,000 | 0.54 | 5.4K | 1,687,988 | — | ↗ |
| 2003-09-30 | WEBB TED FORD | Director | A-Award | D | Stock Option (right to buy) | 30,000 | 0.38 | 11.4K | 30,000 | — | ↗ |
| 2003-08-01 | HAUSMAN MARVIN S MD | Director | X-InTheMoney | D | Purchase Stocks from Warrant Conversion | 43,500 | 0.20 | 8.7K | 78,500 | — | ↗ |
| 2003-07-29 | WOLF THOMAS M | Director | X-InTheMoney | D | Purchase of Stock from Warrant Conversion | 43,500 | 0.20 | 8.7K | 78,500 | — | ↗ |
| 2003-06-30 | WOLF THOMAS M | Director | C-Conversion | A | Preferred Stock to Common Stock | 332,845 | 0.00 | — | 433,626 | — | ↗ |
| 2003-06-30 | HAUSMAN MARVIN S MD | Director | C-Conversion | A | Prefered to Common Stock | 1,113,145 | 0.00 | — | 1,191,145 | — | ↗ |
| 1999-12-31 | REPINE JOHN E | Director | — | D | Non-Statutory Stock Option (Right to Purchase) | 300 | 1.59 | 477.00 | 0 | — | ↗ |
| 1998-12-31 | REPINE JOHN E | Director | — | D | Non-Statutory Stock Option (Right to Purchase) | 300 | 2.50 | 750.00 | 0 | — | ↗ |
| 1996-11-15 | REPINE JOHN E | Director | — | D | Non-Statutory Stock Option (Right to Purchase) | 1,800 | 6.56 | 11.8K | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
10.62M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | Michael Breen Chairman, Chief Executive Officer, and President | 556.2K | 417.2K | — | — | — | 213.6K | 1.19M | 0.00% | ↗ |
| 2 | 2024 | Alan Urban Chief Financial Officer | 218.8K | 87.5K | — | 40.7K | — | 30.9K | 377.8K | 10.77% | ↗ |
| 3 | 2024 | Manu Ohri Former Chief Financial Officer | 203.5K | — | — | — | — | 104.3K | 307.8K | 0.00% | ↗ |
| 4 | 2023 | Michael Breen Executive Chairman of the Board of Directors and Interim Chief Executive Officer | 556.2K | 312.9K | 57.6K | 425.0K | — | 174.2K | 1.53M | 31.63% | ↗ |
| 5 | 2023 | Michael Breen Chairman, Chief Executive Officer, and President | 556.2K | 312.9K | 57.6K | 425.0K | — | 174.2K | 1.53M | 31.63% | ↗ |
| 6 | 2023 | Manu Ohri Chief Financial Officer and Secretary | 432.0K | 172.8K | 57.6K | 425.0K | — | 42.3K | 1.13M | 42.72% | ↗ |
| 7 | 2023 | Manu Ohri Former Chief Financial Officer | 432.0K | 172.8K | 57.6K | 425.0K | — | 42.3K | 1.13M | 42.72% | ↗ |
| 8 | 2022 | Michael Breen Executive Chairman of the Board of Directors and Interim Chief Executive Officer | 492.5K | 386.3K | 689.6K | 111.0K | — | 213.0K | 1.89M | 42.31% | ↗ |
| 9 | 2022 | Dr. Gregory Berk Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | 897.4K | — | — | 111.0K | — | — | 1.01M | 11.01% | ↗ |
| 10 | 2022 | Manu Ohri Chief Financial Officer and Secretary | 334.5K | 140.0K | 248.0K | 200.5K | — | 21.5K | 944.5K | 47.48% | ↗ |
| 11 | 2021 | Anthony Cataldo Former Chief Executive Officer | 479.9K | 559.0K | 9.45M | — | — | 1.8K | 10.49M | 90.08% | ↗ |
| 12 | 2021 | Michael Breen Executive Chairman of the Board of Directors and Interim Chief Executive Officer | 62.8K | 80.0K | 2.45M | — | — | 235.2K | 2.83M | 86.63% | ↗ |
| 13 | 2021 | Michael Handelman Former Chief Financial Officer | 363.6K | 200.0K | 2.25M | — | — | 21.00 | 2.81M | 79.94% | ↗ |
| 14 | 2021 | Dr. Gregory Berk Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | 311.8K | 200.0K | 898.1K | — | — | 14.6K | 1.42M | 63.05% | ↗ |
| 15 | 2021 | Dr. Gavin Choy Former Acting Chief Financial Officer, Chief Clinical Development Officer | 231.6K | 120.0K | — | 607.9K | — | 2.3K | 961.8K | 63.20% | ↗ |
| 16 | 2021 | Dr. Gregory Berk, Former Interim Chief Executive Officer, President of Research & Development and Chief Medical Officer | 311.8K | 200.0K | — | — | — | 1.6K | 513.5K | 0.00% | ↗ |
| 17 | 2021 | Michael Breen Executive Chairman of the Board of Directors | 62.8K | 80.0K | — | — | — | — | 142.8K | 0.00% | ↗ |
| 18 | 2020 | Anthony Cataldo Former Chief Executive Officer | 323.6K | 103.6K | — | — | — | 1.6K | 428.8K | 0.00% | ↗ |
| 19 | 2020 | Michael Handelman Former Chief Financial Officer | 74.8K | — | — | — | — | — | 74.8K | 0.00% | ↗ |
| 20 | 2010 | Anthony J. Cataldo, Chairman and Chief Executive Officer | 180.0K | — | — | — | — | 51.4K | 231.4K | 0.00% | ↗ |
| 21 | 2010 | Bernard Landes, President | 100.0K | — | — | — | — | 51.1K | 151.1K | 0.00% | ↗ |
| 22 | 2010 | Michael Handelman, Chief Financial Officer | 54.0K | — | — | — | — | 5.7K | 59.7K | 0.00% | ↗ |
| 23 | 2006 | Dr. Marvin S. Hausman Chairman of the Board, | 52.1K | — | 165.0K | 208.9K | — | — | 425.9K | 87.77% | ↗ |
| 24 | 2006 | Steven T. Guillen Former President, Chief Executive | 190.0K | — | — | 68.8K | — | 29.4K | 288.2K | 23.86% | ↗ |
| 25 | 2006 | Michael Centron Former Chief | 133.5K | — | — | 29.9K | — | 5.2K | 168.6K | 17.74% | ↗ |
| 26 | 2005 | Steven T. Guillen Former President, Chief Executive | 209.0K | — | — | 111.5K | — | 7.0K | 327.5K | 34.05% | ↗ |
| 27 | 2005 | Steven T. Guillen President, Chief Executive Officer and Director | 209.0K | — | — | 1.10M | — | 2.0K | 211.0K | 521.33% | ↗ |
| 28 | 2005 | Dr. Marvin S. Hausman Chairman of the Board, | — | — | — | 10.3K | — | 15.0K | 25.3K | 40.70% | ↗ |
| 29 | 2005 | Michael Centron Former Chief | — | — | — | — | — | — | — | — | ↗ |
| 30 | 2005 | Dr. Marvin S. Hausman Chairman of the Board, Acting Chief Financial Officer, | — | — | — | 613.0K | — | — | — | — | ↗ |
| 31 | 2004 | Dr. Marvin S. Hausman Chairman of the Board, Acting Chief Financial Officer, | — | — | — | 50.0K | — | — | — | — | ↗ |
| 32 | 2004 | Steven T. Guillen President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 33 | 2003 | Dr. Marvin S. Hausman Chairman of the Board, Acting Chief Financial Officer, | — | — | — | 16.7K | — | — | — | — | ↗ |
| 34 | 2003 | Steven T. Guillen President, Chief Executive Officer and Director | — | — | — | — | — | — | — | — | ↗ |
| 35 | 2001 | Jon S. Pitcher Former Vice President, Chief Financial Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 36 | 2001 | Ray R. Rogers Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 37 | 2001 | Joseph F. Bozman, Jr. Former Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 38 | 2001 | Humberto V. Reyes Former President, OXIS Health Products, Inc., a subsidiary of the Company | — | — | — | — | — | — | — | — | ↗ |
| 39 | 2000 | Jon S. Pitcher Former Vice President, Chief Financial Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
| 40 | 2000 | Ray R. Rogers Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 41 | 2000 | Humberto V. Reyes Former President, OXIS Health Products, Inc., a subsidiary of the Company | — | — | — | — | — | — | — | — | ↗ |
| 42 | 2000 | Joseph F. Bozman, Jr. Former Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 43 | 1999 | Ray R. Rogers Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 44 | 1999 | Joseph F. Bozman, Jr. Former Chairman of the Board, President and Chief Executive Officer | — | — | — | — | — | — | — | — | ↗ |
| 45 | 1999 | Humberto V. Reyes Former President, OXIS Health Products, Inc., a subsidiary of the Company | — | — | — | — | — | — | — | — | ↗ |
| 46 | 1999 | Jon S. Pitcher Former Vice President, Chief Financial Officer and Secretary | — | — | — | — | — | — | — | — | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Martin Breen | President, CEO & Executive Chairman | 1M | male |
| Alan Louis Urban | Chief Financial Officer & Secretary | 626.3K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GTBP
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
